
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
You are part of a select group chosen to receive this survey. Your response to this 3- to 5-minute survey is greatly appreciated. Just click on the secure link below or copy and paste into your browser.






